Michael H. Davidson to Combined Modality Therapy
This is a "connection" page, showing publications Michael H. Davidson has written about Combined Modality Therapy.
Connection Strength
0.162
-
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013 Sep; 35(9):1400-11.e1-3.
Score: 0.088
-
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 04; 334(1):1-6.
Score: 0.026
-
AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr; 19(2):327-36.
Score: 0.021
-
Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16; 363(25):2406-15.
Score: 0.018
-
Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma. Bone Marrow Transplant. 1999 Dec; 24(12):1291-7.
Score: 0.009